JPWO2022165076A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022165076A5 JPWO2022165076A5 JP2023546234A JP2023546234A JPWO2022165076A5 JP WO2022165076 A5 JPWO2022165076 A5 JP WO2022165076A5 JP 2023546234 A JP2023546234 A JP 2023546234A JP 2023546234 A JP2023546234 A JP 2023546234A JP WO2022165076 A5 JPWO2022165076 A5 JP WO2022165076A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- substituted
- unsubstituted
- group
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 20
- 150000001875 compounds Chemical class 0.000 claims 16
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 239000001257 hydrogen Substances 0.000 claims 10
- 125000000547 substituted alkyl group Chemical group 0.000 claims 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 8
- 125000005843 halogen group Chemical group 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 125000003545 alkoxy group Chemical group 0.000 claims 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 125000004404 heteroalkyl group Chemical group 0.000 claims 6
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims 5
- 125000004438 haloalkoxy group Chemical group 0.000 claims 5
- 208000030159 metabolic disease Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 125000003831 tetrazolyl group Chemical group 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 2
- 208000016097 disease of metabolism Diseases 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163143025P | 2021-01-28 | 2021-01-28 | |
| US63/143,025 | 2021-01-28 | ||
| US202163183612P | 2021-05-03 | 2021-05-03 | |
| US63/183,612 | 2021-05-03 | ||
| US202163274893P | 2021-11-02 | 2021-11-02 | |
| US63/274,893 | 2021-11-02 | ||
| PCT/US2022/014156 WO2022165076A1 (en) | 2021-01-28 | 2022-01-27 | Gpcr receptor agonists, pharmaceutical compositions comprising the same, and methods for their use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024505250A JP2024505250A (ja) | 2024-02-05 |
| JP2024505250A5 JP2024505250A5 (https=) | 2025-01-31 |
| JPWO2022165076A5 true JPWO2022165076A5 (https=) | 2025-01-31 |
Family
ID=80447497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023546234A Pending JP2024505250A (ja) | 2021-01-28 | 2022-01-27 | Ｇｐｃｒ受容体アゴニスト、それを含む医薬組成物、及びそれらの使用方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US20230089073A1 (https=) |
| EP (2) | EP4284795A1 (https=) |
| JP (1) | JP2024505250A (https=) |
| KR (1) | KR20230152011A (https=) |
| AU (1) | AU2022212019A1 (https=) |
| BR (1) | BR112023015045A2 (https=) |
| CA (1) | CA3209593A1 (https=) |
| CL (2) | CL2023002204A1 (https=) |
| CO (1) | CO2023011071A2 (https=) |
| CR (1) | CR20230330A (https=) |
| EC (1) | ECSP23057029A (https=) |
| GE (1) | GEAP202316333A (https=) |
| IL (1) | IL304521A (https=) |
| JO (1) | JOP20230167A1 (https=) |
| MX (1) | MX2023008854A (https=) |
| PE (1) | PE20231814A1 (https=) |
| WO (1) | WO2022165076A1 (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI4143183T3 (fi) | 2020-04-29 | 2026-01-07 | Gasherbrum Bio Inc | Heterosyklisiä glp-1-agonisteja |
| PE20231181A1 (es) | 2020-08-06 | 2023-08-11 | Gasherbrum Bio Inc | Agonistas del glp-1 heterociclicos |
| WO2022042691A1 (en) * | 2020-08-28 | 2022-03-03 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| IL310377A (en) * | 2021-08-30 | 2024-03-01 | Mindrank Ai Ltd | Novel aryl ether substituted heterocyclic compound as glp1r agonist |
| KR20240068737A (ko) | 2021-09-27 | 2024-05-17 | 테른스 파마슈티칼스, 인크. | Glp-1r 효능제로서의 벤즈이미다졸 카복실산 |
| WO2023057429A1 (en) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators |
| AU2022358915A1 (en) | 2021-10-05 | 2024-05-09 | Astrazeneca Ab | Certain 2,5-diazabicyclo[4.2.0]octanes as glp-1 receptor modulators |
| WO2023057414A1 (en) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certain octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators |
| AU2022375634A1 (en) | 2021-10-25 | 2024-06-06 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
| WO2023111145A1 (en) | 2021-12-16 | 2023-06-22 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| US20250066338A1 (en) | 2021-12-16 | 2025-02-27 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| KR20240150488A (ko) | 2022-02-23 | 2024-10-15 | 테른스 파마슈티칼스, 인크. | Glp-1r 작용제로서의 화합물 |
| CN117362282B (zh) * | 2022-07-07 | 2026-04-21 | 杭州德睿智药科技有限公司 | Glp-1r激动剂的盐及其制备方法和应用 |
| AU2023310481A1 (en) * | 2022-07-18 | 2025-03-06 | Mindrank Therapeutics (Suzhou) New Drug Research And Development Co., Ltd | Polymorphic form of glp-1r agonist, preparation method therefor and use thereof |
| CN119923395A (zh) * | 2022-07-27 | 2025-05-02 | 卡莫特医疗有限公司 | N-杂环gpcr受体激动剂、包含其的药物组合物和其使用方法 |
| WO2024051700A1 (zh) * | 2022-09-05 | 2024-03-14 | 德睿智药(苏州)新药研发有限公司 | 作为glp1r激动剂的新型芳基氘代苄醚取代杂环类化合物 |
| IL319453A (en) * | 2022-09-06 | 2025-05-01 | Mindrank Therapeutics Suzhou New Drug Res And Development Co Ltd | Polymorph of a GLP-1R agonist compound, method of preparation thereof and use thereof |
| CN116102543B (zh) * | 2022-10-21 | 2025-07-22 | 江南大学 | 一种glp-1r激动剂、合成方法及其用途 |
| WO2024102625A1 (en) | 2022-11-11 | 2024-05-16 | Eli Lilly And Company | Glucagon-like peptide 1 receptor agonists |
| IL320810A (en) | 2022-11-16 | 2025-07-01 | Lilly Co Eli | Glucagon-like peptide 1 receptor agonists |
| CN120693338A (zh) * | 2022-12-22 | 2025-09-23 | 加舒布鲁姆生物公司 | 杂环的glp-1激动剂 |
| WO2024153041A1 (zh) * | 2023-01-19 | 2024-07-25 | 杭州德睿智药科技有限公司 | Glp-1r激动剂的制造方法与中间体及其用途 |
| US20240398794A1 (en) | 2023-04-07 | 2024-12-05 | Terns Pharmaceuticals, Inc. | COMBINATIONS OF GLP-1R AND THRß AGONISTS AND METHODS OF USE THEREOF |
| TW202521533A (zh) | 2023-09-14 | 2025-06-01 | 香港商歌禮製藥(中國)有限公司 | Glp-1r 激動劑及其治療方法 |
| US12291530B1 (en) | 2023-11-24 | 2025-05-06 | Ascletis Pharma (China) Co., Limited | GLP-1R agonist and therapeutic method thereof |
| WO2025128564A1 (en) | 2023-12-11 | 2025-06-19 | Carmot Therapeutics, Inc. | Salt forms of a glp-1 receptor modulator |
| WO2025128561A1 (en) | 2023-12-11 | 2025-06-19 | Carmot Therapeutics, Inc. | Crystalline forms of a glp-1 receptor modulator |
| WO2025158275A1 (en) | 2024-01-24 | 2025-07-31 | Pfizer Inc. | Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds |
| WO2025189141A1 (en) | 2024-03-08 | 2025-09-12 | Annapurna Bio, Inc. | Methods for treating obesity and increasing weight loss |
| WO2025259888A1 (en) | 2024-06-13 | 2025-12-18 | Carmot Therapeutics Inc. | Method of treating diabetes using a glp-1 receptor agonist |
| WO2026047102A1 (en) | 2024-08-29 | 2026-03-05 | F. Hoffmann-La Roche Ag | Process for the preparation of pyrimidine derivatives |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2004613A2 (en) * | 2006-03-31 | 2008-12-24 | AstraZeneca AB | Bicyclic benzimidazole compounds and their use as metabotropic glutamate receptor potentiators |
| CN101553483B (zh) * | 2006-12-13 | 2013-04-17 | 弗·哈夫曼-拉罗切有限公司 | 作为非核苷逆转录酶抑制剂的2-(哌啶-4-基)-4-苯氧基-或苯基氨基-嘧啶衍生物 |
| EP3555064B9 (en) * | 2016-12-16 | 2023-03-01 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
| CA3045644C (en) | 2018-06-13 | 2024-01-16 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
| CR20210341A (es) * | 2018-11-22 | 2021-11-25 | Qilu Regor Therapeutics Inc | Agonistas de glp-ir y usos de los mismos |
| US10954221B2 (en) | 2019-04-12 | 2021-03-23 | Qilu Regor Therapeutics Inc. | GLP-1R agonists and uses thereof |
| AU2020256647B2 (en) * | 2019-04-12 | 2025-07-31 | Qilu Regor Therapeutics Inc. | GLP-1R agonists and uses thereof |
| WO2020234726A1 (en) | 2019-05-20 | 2020-11-26 | Pfizer Inc. | Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases |
| TWI751585B (zh) | 2019-06-28 | 2022-01-01 | 美商美國禮來大藥廠 | 類升糖素肽1受體促效劑 |
| JP7386997B2 (ja) * | 2019-11-15 | 2023-11-27 | イルドン ファーマシューティカル カンパニー リミテッド | Ｇｌｐ－１受容体アゴニストおよびその使用 |
| TW202144340A (zh) * | 2020-04-03 | 2021-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用 |
| FI4143183T3 (fi) * | 2020-04-29 | 2026-01-07 | Gasherbrum Bio Inc | Heterosyklisiä glp-1-agonisteja |
| PE20231206A1 (es) * | 2020-08-21 | 2023-08-17 | Terns Pharmaceuticals Inc | Compuestos como agonistas de glp-1r |
| WO2022042691A1 (en) * | 2020-08-28 | 2022-03-03 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| AU2021306414B2 (en) * | 2020-09-01 | 2026-01-29 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Fused imidazole derivative, preparation method therefor, and medical use thereof |
| IL310377A (en) | 2021-08-30 | 2024-03-01 | Mindrank Ai Ltd | Novel aryl ether substituted heterocyclic compound as glp1r agonist |
-
2022
- 2022-01-27 CA CA3209593A patent/CA3209593A1/en active Pending
- 2022-01-27 JP JP2023546234A patent/JP2024505250A/ja active Pending
- 2022-01-27 CR CR20230330A patent/CR20230330A/es unknown
- 2022-01-27 KR KR1020237029178A patent/KR20230152011A/ko active Pending
- 2022-01-27 AU AU2022212019A patent/AU2022212019A1/en active Pending
- 2022-01-27 EP EP22704219.9A patent/EP4284795A1/en active Pending
- 2022-01-27 GE GEAP202316333A patent/GEAP202316333A/en unknown
- 2022-01-27 US US17/586,751 patent/US20230089073A1/en not_active Abandoned
- 2022-01-27 US US18/262,956 patent/US20240252492A1/en not_active Abandoned
- 2022-01-27 MX MX2023008854A patent/MX2023008854A/es unknown
- 2022-01-27 PE PE2023002212A patent/PE20231814A1/es unknown
- 2022-01-27 WO PCT/US2022/014156 patent/WO2022165076A1/en not_active Ceased
- 2022-01-27 BR BR112023015045A patent/BR112023015045A2/pt unknown
- 2022-01-27 EP EP25162106.6A patent/EP4563199A3/en active Pending
-
2023
- 2023-07-17 IL IL304521A patent/IL304521A/en unknown
- 2023-07-26 JO JOJO/P/2023/0167A patent/JOP20230167A1/ar unknown
- 2023-07-26 CL CL2023002204A patent/CL2023002204A1/es unknown
- 2023-07-27 EC ECSENADI202357029A patent/ECSP23057029A/es unknown
- 2023-08-24 CO CONC2023/0011071A patent/CO2023011071A2/es unknown
-
2024
- 2024-04-11 US US18/632,736 patent/US20250092025A1/en not_active Abandoned
- 2024-08-08 CL CL2024002388A patent/CL2024002388A1/es unknown
-
2025
- 2025-01-14 US US19/020,628 patent/US12459929B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2022165076A5 (https=) | ||
| JPWO2022256702A5 (https=) | ||
| CN1045293C (zh) | 取代的吡唑类化合物及含其的药物组合物 | |
| CA2909742C (en) | Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis b | |
| JP2016512536A5 (https=) | ||
| JP2016512534A5 (https=) | ||
| RU2287522C2 (ru) | Замещенные кислотными группами дифенилазетидиноны, способ их получения, содержащие эти соединения лекарственные средства и их применение | |
| CA2952541A1 (en) | Pyridazones and triazinones for the treatment and prophylaxis of hepatitis b virus infection | |
| ZA200103942B (en) | Pyrrolidine derivatives-CCR-3 receptor antagonists. | |
| SK280882B6 (sk) | Cyklické močoviny, ich analógy a farmaceutické prípravky na ich báze | |
| JP2018510852A5 (https=) | ||
| EP1240160A1 (en) | Substituted pyridazines having cytokine inhibitory activity | |
| JP2012503664A5 (https=) | ||
| EP0303697A1 (en) | Derivatives of physiologically active substance k-252 | |
| JPH0940607A (ja) | 新規芳香族化合物、その製造方法、製造の中間体および前記化合物を含有する苦痛緩和治療用医薬組成物 | |
| CZ20013449A3 (cs) | Deriváty diarylu a jejich pouľití jako léčiva | |
| PL148590B1 (en) | Method of obtaining novel derivatives of 2-amino-5-hydroxy-4-methylpyrimidine | |
| ES2510490T3 (es) | Agentes receptores de la histamina H3, preparación y usos terapéuticos | |
| IE921079A1 (en) | N-arylheteroarylalkyl-imidazol-2-one compounds for treatment¹of circulatory disorders | |
| JP2005513125A5 (https=) | ||
| WO2009042093A1 (en) | Hiv protease inhibitors | |
| JP2007502815A5 (https=) | ||
| TW200825075A (en) | Sulfonylurea derivatives as a selective MMP-13 inhibitor | |
| JP2025032196A5 (https=) | ||
| FI82450C (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbara difenyl- och fenylpyridylderivat. |